-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cadonilimab in Signet Ring Cell Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Signet Ring Cell Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cadonilimab in Signet Ring Cell Squamous Cell Carcinoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ST101 in Signet Ring Cell Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ST101 in Signet Ring Cell Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ST101 in Signet Ring Cell Squamous Cell Carcinoma...
-
Company Insights
Innovation and Patenting activity of Signet Jewelers Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Signet Jewelers Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ST101 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ST101 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ST101 in Metastatic Breast Cancer Drug Details: ST-101 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ST101 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ST101 in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ST101 in Sarcomas Drug Details: ST-101 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ST101 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ST101 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ST101 in Glioblastoma Multiforme (GBM) Drug Details: ST-101 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ST101 in Gastrointestinal Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ST101 in Gastrointestinal Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ST101 in Gastrointestinal Tract Cancer Drug Details: ST-101 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ST101 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ST101 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ST101 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: ST-101 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cadonilimab in Rectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Rectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cadonilimab in Rectal Cancer Drug Details: Cardinalizumab (Ketanil) is a bi-specific...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cadonilimab in Vulvar Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Vulvar Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cadonilimab in Vulvar Cancer Drug Details: Cardinalizumab (Ketanil) is a bi-specific...